Lynch Regenerative Medicine Names General Counsel, CMO

Lynch Regenerative Medicine (LRM), a regenerative medicine company focused on platelet-derived growth factor–based therapies, has named Madison Dini as General Counsel and Chad Lindemann as Chief Marketing Officer.

According to the company, Dini will lead legal, compliance, and corporate governance efforts as LRM advances its clinical portfolio. She joins the organization from Michelman & Robinson, LLP, where she served as a partner advising life sciences companies on regulatory, compliance, and litigation matters. Her experience includes acting as outside general counsel and lead trial counsel in complex business disputes. Dini has also spoken publicly on legal and regulatory issues related to regenerative medicine.

In a statement, Dini said her decision to join LRM followed an evaluation of the company’s scientific and compliance frameworks, adding that she intends to support what she described as responsible innovation in the field.

Lindemann will oversee marketing strategy for LRM’s current and future product portfolio. He brings approximately 20 years of experience in medical aesthetics sales and marketing. Most recently, he served as Vice President of Marketing at Allergan Aesthetics, where he led marketing efforts for brands including BOTOX Cosmetic, JUVÉDERM, CoolSculpting, and SkinMedica.

In a company statement, Lindemann emphasized the importance of communicating evidence-based information to clinicians and patients in a rapidly evolving digital landscape.

LRM Chief Executive Officer Samuel Lynch, MD, said the appointments are intended to support the company’s continued development and navigation of the regulatory and commercial environment surrounding regenerative medicine therapies.